Clinical Trials Browser

Phase 2 × Antigens × Gastrointestinal × Clear all

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular